Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation

Molecular Carcinogenesis

Volumn 55, Issue 1, 2016, Pages 3-14

  Tilley, Cynthia ^a   Deep, Gagan ^a,b   Agarwal, Chapla ^a,b   Wempe, Michael F ^a,b   Biedermann, David ^c   Valentová, Kateřina ^c   Kren, Vladimir ^c   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Basal cell carcinoma; Chemoprevention; Dehydrosilibinin; EGFR; Mitogenic signaling; Phytochemicals; Silibinin

Indexed keywords

2,3 DEHYDROSILIBININ; ANTINEOPLASTIC AGENT; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SILIBININ; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; ANTIOXIDANT; SILYMARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER TISSUE; CELL CULTURE; CELL GROWTH; CHEMOPROPHYLAXIS; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; MITOGENICITY; MOUSE; MURINE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ALLOGRAFT; ANIMAL; CARCINOMA, BASAL CELL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ALLOGRAFTS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, BASAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; MICE; MICE, KNOCKOUT; NF-KAPPA B; SIGNAL TRANSDUCTION; SILYMARIN; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS; TUMOR STEM CELL ASSAY;

EID: 84954403243     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22253     Document Type: Article

References (52)

1. Wu S, Han J, Li WQ, Li T, Qureshi AA. Basal-cell carcinoma incidence and associated risk factors in U.S. women and men. Am J Epidemiol 2013; 178:890-897.
2. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. Hedgehog signalling in skin development and cancer. Exp Dermatol 2006; 15:667-677.
3. Epstein EH. Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer 2008; 8:743-754.
4. Mimeault M, Batra SK. Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev 2010; 62:497-524.
5. Tang JY, Aszterbaum M, Athar M, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1 + /- humans and mice. Cancer Prev Res (Phila) 2010; 3:25-34.
6. So PL, Lee K, Hebert J, et al. Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1 + /- mice exposed to ultraviolet or ionizing radiation. Cancer Res 2004; 64:4385-4389.
7. Weinstock MA, Bingham SF, Digiovanna JJ, et al. Tretinoin and the prevention of keratinocyte carcinoma (Basal and squamous cell carcinoma of the skin): A veterans affairs randomized chemoprevention trial. J Invest Dermatol 2012; 132:1583-1590.
8. Zhang B, Liang X, Ye L, Wang Y. No chemopreventive effect of nonsteroidal anti-inflammatory drugs on nonmelanoma skin cancer: Evidence from meta-analysis. PLoS ONE 2014; 9:e96887.
9. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma-Molecular biology and potential new therapies. J Clin Invest 2012; 122:455-463.
10. Eberl M, Klingler S, Mangelberger D, et al. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol Med 2012; 4:218-233.
11. Schnidar H, Eberl M, Klingler S, et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res 2009; 69:1284-1292.
12. Gu D, Fan Q, Zhang X, Xie J. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem 2012; 287:38356-38366.
13. Bickers DR, Athar M. Novel approaches to chemoprevention of skin cancer. J Dermatol 2000; 27:691-695.
14. Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 2005; 41:1969-1979.
15. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis 2004; 25:1459-1465.
16. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling. Neoplasia 2010; 12:415-424.
17. Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin 2007; 28:1466-1475.
18. Cheung CW, Gibbons N, Johnson DW, Nicol DL. Silibinin-A promising new treatment for cancer. Anticancer Agents Med Chem 2010; 10:186-195.
19. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008; 269:352-362.
20. Gazak R, Svobodova A, Psotova J, et al. Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 2004; 12:5677-5687.
21. Biedermann D, Vavrikova E, Cvak L, Kren V. Chemistry of silybin. Nat Prod Rep 2014; 31:1138-1157.
22. Agarwal C, Wadhwa R, Deep G, et al. Anti-cancer efficacy of silybin derivatives-A structure-activity relationship. PLoS ONE 2013; 8:e60074.
23. Gažák R, Trouillas P, Biedermann D, et al. Base-catalyzed oxidation of silybin and isosilybin into 2, 3-dehydro derivatives. Tetrahedron Lett 2013; 54:315-317.
24. Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: Targeting the activation of NF-kappaB signaling. Mol Carcinog 2013; 52:195-206.
25. Deep G, Kumar R, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits fibronectin induced motility, invasiveness and survival in human prostate carcinoma PC3 cells via targeting integrin signaling. Mutat Res Fundam Mol Mech Mutagen 2014; 768:35-46.
26. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007; 28:1463-1470.
27. Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther 2008; 7:1817-1826.
28. Deep G, Raina K, Singh RP, Oberlies NH, Kroll DJ, Agarwal R. Isosilibinin inhibits advanced human prostate cancer growth in athymic nude mice: Comparison with silymarin and silibinin. Int J Cancer 2008; 123:2750-2758.
29. Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G, Agarwal R. Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res 2010; 27:2085-2097.
30. Derry MM, Raina K, Balaiya V, et al. Grape seed extract efficacy against azoxymethane-induced colon tumorigenesis in A/J mice: Interlinking miRNA with cytokine signaling and inflammation. Cancer Prev Res (Phila) 2013; 6:625-633.
31. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59:21-26.
32. Dormoy V, Danilin S, Lindner V, et al. The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth. Mol Cancer 2009; 8:123.
33. Nakashima H, Nakamura M, Yamaguchi H, et al. Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Res 2006; 66:7041-7049.
34. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol 2011; 12:695-708.
35. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-1293.
36. Fresno Vara, Casado JA, de Castro E, Cejas J, Belda-Iniesta P, Gonzalez-Baron C. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30:193-204.
37. Gu M, Dhanalakshmi S, Mohan S, Singh RP, Agarwal R. Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis 2005; 26:1404-1413.
38. Gu M, Dhanalakshmi S, Singh RP, Agarwal R. Dietary feeding of silibinin prevents early biomarkers of UVB radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Cancer Epidemiol Biomarkers Prev 2005; 14:1344-1349.
39. Gu M, Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Res 2007; 67:3483-3491.
40. Bigelow RL, Jen EY, Delehedde M, Chari NS, McDonnell TJ. Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes. J Invest Dermatol 2005; 124:457-465.
41. So PL, Wang GY, Wang K, et al. PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis. Cancer Prev Res (Phila) 2014; 7:407-417.
42. Tewari- Singh N, Jain AK, Inturi S, Agarwal C, White CW, Agarwal R. Silibinin attenuates sulfur mustard analog-induced skin injury by targeting multiple pathways connecting oxidative stress and inflammation. PLoS ONE 2012; 7:e46149.
43. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107:135-142.
44. Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-kappaB, and AP-1 activation in RAW264.7 cells. Mol Carcinog 2014; 53:169-180.
45. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240-246.
46. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3:859-868.
47. Urabe A, Nakayama J, Taniguchi S, Kuroki R, Hori Y. Expression of the fos oncogene in basal cell carcinoma. J Dermatol Sci 1994; 8:50-53.
48. Bonifas JM, Pennypacker S, Chuang PT, et al. Activation of expression of hedgehog target genes in basal cell carcinomas. J Invest Dermatol 2001; 116:739-742.
49. Rubin AI, Chen EH, Ratner D. Basal-Cell Carcinoma. N Engl J Med 2005; 353:2262-2269.
50. Hetal TB, Bindesh P, Sneha, T. A review on techniques for oral bioavailability enhancement of drugs. Nalt J Pharm Sci Rev Res 2010; 4:203-223.
51. Dunnick JK, Nyska A, Bishop JB, et al. Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 2011;1-177.
52. Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 24:1423-1432.